Cantor Fitzgerald Cuts Earnings Estimates for Affimed

Affimed (NASDAQ:AFMD) – Stock analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for Affimed in a report issued on Tuesday, November 19th. Cantor Fitzgerald analyst L. Watsek now expects that the biopharmaceutical company will earn ($4.06) per share for the year, down from their previous forecast of ($3.71). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative net margin of 7,836.26% and a negative return on equity of 193.84%. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million.

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus dropped their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research note on Friday, November 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Affimed has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Affimed Stock Down 0.8 %

NASDAQ:AFMD opened at $2.62 on Friday. Affimed has a 1-year low of $2.61 and a 1-year high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. The firm has a 50-day moving average of $3.38 and a two-hundred day moving average of $4.43.

Hedge Funds Weigh In On Affimed

Several large investors have recently added to or reduced their stakes in the company. Choreo LLC bought a new stake in Affimed during the second quarter valued at $54,000. Intellectus Partners LLC grew its position in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the last quarter. Jane Street Group LLC acquired a new stake in Affimed during the third quarter worth about $44,000. FMR LLC lifted its holdings in Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the period. 30.82% of the stock is currently owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.